The COVID-19 vaccine from Pfizer and BioNTech is highly effective against symptomatic COVID-19 for at least six months after a second dose, a new analysis has shown.
The companies on Thursday announced that in an analysis of its phase 3 study that included 927 symptomatic COVID-19 cases, the vaccine was 91.3 percent effective "measured seven days through up to six months after the second dose." It was also 100 percent effective against severe disease as defined by the CDC, as well as 95.3 percent effective against severe disease as defined by the FDA, the companies said. There were no serious safety concerns.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
'If you keep people permanently unhappy, you cannot have a stable society'Instant Opinion Opinion, comment and editorials of the day
-
The Nare Hotel: a charming hideaway on the Cornish coastThe Week Recommends Upgrade your classic seaside holiday at this five-star country house hotel
-
Today's political cartoons - March 6, 2025Cartoons Thursday's cartoons - weird science, Hoover's heels, and more
-
Texas outbreak brings 1st US measles death since 2015Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
-
Mystery illness spreading in Congo rapidly kills dozensSpeed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
-
Ozempic can curb alcohol cravings, study findsSpeed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
-
New form of H5N1 bird flu found in US dairy cowsSpeed Read This new form of bird flu is different from the version that spread through herds in the last year
-
Microplastics accumulating in human brains, study findsSpeed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
-
FDA approves painkiller said to thwart addictionSpeed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
-
Study finds possible alternative abortion pillSpeed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
